Abstracts

179 – Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects

Background People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVD) and accelerated aging, including frailty. REPRIEVE demonstrated a 36% reduction in the hazard of major adverse cardiovascular events (MACE) for pitavastatin vs placebo among PWH, but little is known about statins for ASCVD prevention among PWH with frailty.  The goal of…

180 – Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection

Background Epigenetic age acceleration has prognostic value in the general population. However, its role in predicting clinical outcomes in people with HIV (PWH) with long-term virological suppression remains unclear Methods Retrospective cohort of PWH with long-term virological suppression, followed at a single HIV unit. Blood DNA methylation was assessed using the Illumina Infinium MethylationEPIC BeadChip,…

122 – Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study

Background Dolutegravir (DTG) is not recommended for neonates due to absence of dosing guidelines and safety information. We are evaluating the multi-dose pharmacokinetics (PK) and safety of two pediatric DTG formulations in neonates: a dispersible scored tablet (DTG-DT, 10 mg) and a novel oral dispersible film (DTG-OF, 5 mg). Methods PETITE-DTG is an ongoing phase…

110 – HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023

Background The global burden of viral hepatitis B (HBV) is substantial, and monitoring progress across the care cascade is essential to plan elimination strategies. In Sub-Saharan Africa, data on the HBV care cascade are limited. We examined the HBV care cascade in Rwanda from 2016 to 2023. Methods In this population-based retrospective cohort study, we used routinely…

156 – Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir

Background Tenofovir-lamuvidine-dolutegravir (TLD) is highly effective as ART but the causes of virologic failure (VF) in individuals on TLD without integrase (IN) resistance mutations are not well understood. Off-target mutations in nucleocapsid (NC) have been selected in vitro and are associated with decreased DTG susceptibility in vitro. Samples from ACTG study A5381 were examined to…

171 – Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV

Background Alzheimer’s disease (AD) is the leading cause of dementia worldwide, and accurate diagnosis is crucial, including for people with HIV (PWH). Blood-based biomarkers for AD offer a promising, low-cost, non-invasive diagnostic alternative, but data are limited in PWH. Our study measured phosphorylated tau 217 (p-tau217)–the only blood-based biomarker currently recommended for diagnosing AD–and assessed…

153 – Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor

Background New long-acting antiretroviral therapy (ART) regimens are needed to expand treatment choices for people living with HIV-1. VH4011499 (VH-499) is a new HIV-1 capsid inhibitor in development as a long-acting antiretroviral agent for the treatment and prevention of HIV-1. Here, we present antiviral effect, pharmacokinetics, safety, and tolerability data for VH-499 from a proof-of-concept,…